After Medtronic lobbying push, the FDA had change of heart.
作者信息
Mathews Anna Wilde, Burton Thomas M
出版信息
Wall St J (East Ed). 2004 Jul 9:A1, A7.
PMID:15290811
Abstract
摘要
相似文献
1
After Medtronic lobbying push, the FDA had change of heart.
Wall St J (East Ed). 2004 Jul 9:A1, A7.
2
Regarding "Withdrawal of article by the FDA after objection from Medtronic".
J Vasc Surg. 2004 Sep;40(3):594. doi: 10.1016/j.jvs.2004.07.014.
3
Misperceptions regarding the long-term safety of the AneuRx stent graft.
J Vasc Surg. 2004 Sep;40(3):594-5. doi: 10.1016/j.jvs.2004.07.016.
4
Inappropriate industry influence on FDA processes.
J Vasc Surg. 2004 Sep;40(3):594. doi: 10.1016/j.jvs.2004.07.015.
5
Regarding "withdrawal of article by the FDA after objection from Medtronic".
J Vasc Surg. 2004 Oct;40(4):835-6. doi: 10.1016/j.jvs.2004.08.011.
6
Watchdog group says "massive lobbying effort" by medical device industry threatens public health.
BMJ. 2012 Feb 28;344:e1521. doi: 10.1136/bmj.e1521.
7
Medical device regs: are they doing the job? FDA and industry share common goal of device safety.
AORN J. 1981 Apr;33(5):949-54.
8
Medical devices: problems on the rise.
Consum Rep. 2007 Dec;72(12):53.
9
FDA and industry happenings.
J Interv Cardiol. 2007 Oct;20(5):406-8. doi: 10.1111/j.1540-8183.2007.00288.x.
10
FDA has a change of heart.
Mater Manag Health Care. 2006 May;15(5):9.
Zotero 插件